Connect with us

Food and Diet

Nestle Planning New Line of “Ozempic Foods”

sign-worlds-biggest-food-company-nestle

Nestle is set to introduce a new line of high-fiber, protein-packed foods targeting Americans on weight management journeys, particularly those using GLP-1 medications like Wegovy and Ozempic. The new product line, named Vital Pursuit foods, aims to support a balanced diet and meet the specific needs of consumers taking semaglutide medications.

The Vital Pursuit foods will include twelve newly designed items such as whole grain bowls, sandwich melts, and pizzas. These products are set to hit select stores nationwide toward the end of the year. Tom Moe, president of Nestle USA Meals Division, emphasized the importance of providing options to support the individualized needs of consumers on health journeys. 

GLP-1 medications, originally prescribed for managing Type 2 diabetes due to their blood sugar regulation benefits, have gained popularity for their effectiveness in reducing appetite. This appetite suppression leads to reduced food intake, which has sparked concerns among food retailers about potential impacts on profits.

In response to the growing use of these medications, Nestle sees an opportunity to cater to this expanding market. With approximately 9 million prescriptions written for GLP-1 medications in the fourth quarter of 2022 and expectations of this number reaching 30 million by 2030, the market for semaglutide medications is projected to exceed $100 billion.

Strategic Moves by Nestle and Other Food Producers

Nestle’s initiative follows similar moves by other food producers. Daily Harvest launched a GLP-1 medication-friendly line of foods earlier this year, and Abbott Laboratories announced a protein-laden drink suitable for consumers on GLP-1 medications. Nestle, known for brands like DiGiorno pizza and Stouffer’s frozen meals, plans to price each Vital Pursuit food item at $4.99, though retailers may adjust this price.  

Additionally, Nestle CEO Mark Schneider revealed that the company is developing supplements to help GLP-1 medication users obtain necessary vitamins and nutrients while consuming fewer calories.  

Nestle’s introduction of Vital Pursuit foods reflects a strategic response to the increasing popularity of GLP-1 medications for weight management. By offering high-fiber, protein-packed food options tailored to the needs of those on semaglutide medications, Nestle aims to support balanced diets and capitalize on the expanding market of weight-conscious consumers. This move underscores the company’s commitment to adapting to changing consumer needs and enhancing health and wellness offerings.

Will you be eating Nestle’s “Ozempic food?” Leave your thoughts in the comments below.